Centrus Energy Corp. (LEU)
NYSEEnergyUraniumSnapshot 2026-10-30
NYSEEnergyUraniumSnapshot 2026-10-30
Research Workspace
Put LEU beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Energy is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 8% over the past year and decelerating.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 13%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 24% growth a year, above the roughly 0% analysts expect, leaving little room for error.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 74% in its worst 12-month stretch.
View RiskLEU’s HALEU supply chain with advanced reactor partners must scale to support its growth case. Revenue grew 14% year over year, and Q2 FY2026 earnings beat consensus. LEU trades at 37× earnings versus the 22× peer median. The market prices in more growth than our forecast. Its fragile cash backing and 29% next-quarter miss probability threaten that premium. Peer multiples imply a price about 24% below where it trades (it looks expensive on this basis). Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-30. LEU is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering LEU (as of Oct 2026).
Based on 11 Wall Street analysts offering 12-month price targets for LEU in the last 4 months.
Continue this research
Compare LEU with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LEU Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 8 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Coal & Consumable Fuels — fair value, gap to price, and forward P/E.
Compare the value case
Put LEU next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Invest in centrifuge manufacturing and expansion
First newly manufactured centrifuge demonstrates progress in domestic manufacturing and supports planned Piketon capacity expansion.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $103.29
The last 12 months of price, then the range of analyst 12-month targets from today’s $103.29.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Reported $116 million acquisition is a material strategic and capital-allocation development.

Advances: Establish commercial HALEU supply chain with advanced reactor partners
Buy rating supports HALEU supply chain objective.

Advances: Establish commercial HALEU supply chain with advanced reactor partners
New HALEU deal supports supply chain establishment.

Advances: Establish commercial HALEU supply chain with advanced reactor partners
Secures commercial HALEU supply chain with a key partner.

Threatens: Capital deployment guidance for 2026
Dilution from offering may impact capital deployment plans.

Advances: Expand uranium enrichment facility at Piketon and Oak Ridge
Centrifuge production supports facility expansion objectives.
